ArticleWorld journal of gastroenterology2007

Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.

Viola Baradari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.